Morgan Stanley’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.7M | Sell |
961,050
-143,707
| -13% | -$2.95M | ﹤0.01% | 2908 |
|
|
2026
Q1 | $21.2M | Sell |
1,104,757
-115,097
| -9% | -$2.29M | ﹤0.01% | 2901 |
|
|
2025
Q4 | $20.1M | Sell |
1,219,854
-469,638
| -28% | -$7.93M | ﹤0.01% | 2928 |
|
|
2025
Q3 | $24.5M | Buy |
1,689,492
+377,476
| +29% | +$5.42M | ﹤0.01% | 2695 |
|
|
2025
Q2 | $18.4M | Buy |
1,312,016
+58,413
| +5% | +$822K | ﹤0.01% | 2898 |
|
|
2025
Q1 | $17M | Buy |
1,253,603
+24,463
| +2% | +$469K | ﹤0.01% | 2858 |
|
|
2024
Q4 | $25M | Sell |
1,229,140
-515,615
| -30% | -$13.2M | ﹤0.01% | 2543 |
|
|
2024
Q3 | $50.8M | Buy |
1,744,755
+520,877
| +43% | +$12.9M | ﹤0.01% | 1812 |
|
|
2024
Q2 | $28.4M | Buy |
1,223,878
+295,752
| +32% | +$5.68M | ﹤0.01% | 2289 |
|
|
2024
Q1 | $19M | Sell |
928,126
-49,367
| -5% | -$928K | ﹤0.01% | 2755 |
|
|
2023
Q4 | $21M | Sell |
977,493
-4,076
| -0.4% | -$80.7K | ﹤0.01% | 2638 |
|
|
2023
Q3 | $20.2M | Sell |
981,569
-95,317
| -9% | -$2.42M | ﹤0.01% | 2433 |
|
|
2023
Q2 | $31.8M | Buy |
1,076,886
+507,764
| +89% | +$14.3M | ﹤0.01% | 2006 |
|
|
2023
Q1 | $13.1M | Buy |
569,122
+136,636
| +32% | +$3.76M | ﹤0.01% | 2882 |
|
|
2022
Q4 | $12M | Sell |
432,486
-248,846
| -37% | -$7.4M | ﹤0.01% | 2894 |
|
|
2022
Q3 | $20.9M | Buy |
681,332
+258,321
| +61% | +$8.4M | ﹤0.01% | 2140 |
|
|
2022
Q2 | $12.4M | Sell |
423,011
-282,644
| -40% | -$7.4M | ﹤0.01% | 2837 |
|
|
2022
Q1 | $22.7M | Buy |
705,655
+418,397
| +146% | +$14.4M | ﹤0.01% | 1984 |
|
|
2021
Q4 | $12.8M | Sell |
287,258
-96,735
| -25% | -$4.58M | ﹤0.01% | 2655 |
|
|
2021
Q3 | $19.4M | Sell |
383,993
-47,039
| -11% | -$2.65M | ﹤0.01% | 2119 |
|
|
2021
Q2 | $33.8M | Sell |
431,032
-31,128
| -7% | -$1.93M | ﹤0.01% | 1628 |
|
|
2021
Q1 | $26.4M | Buy |
462,160
+242,732
| +111% | +$16.2M | ﹤0.01% | 1669 |
|
|
2020
Q4 | $18.4M | Sell |
219,428
-85,432
| -28% | -$5.16M | ﹤0.01% | 1885 |
|
|
2020
Q3 | $10.9M | Sell |
304,860
-14,067
| -4% | -$424K | ﹤0.01% | 1954 |
|
|
2020
Q2 | $7.71M | Buy |
318,927
+163,505
| +105% | +$3.84M | ﹤0.01% | 2212 |
|
|
2020
Q1 | $2.72M | Sell |
155,422
-93,387
| -38% | -$1.95M | ﹤0.01% | 3073 |
|
|
2019
Q4 | $4.33M | Buy |
248,809
+85,709
| +53% | +$1.43M | ﹤0.01% | 3347 |
|
|
2019
Q3 | $2.5M | Buy |
163,100
+17,025
| +12% | +$325K | ﹤0.01% | 3583 |
|
|
2019
Q2 | $3.03M | Buy |
146,075
+14,183
| +11% | +$318K | ﹤0.01% | 3418 |
|
|
2019
Q1 | $3.06M | Sell |
131,892
-72,322
| -35% | -$1.51M | ﹤0.01% | 3194 |
|
|
2018
Q4 | $4.22M | Buy |
204,214
+17,312
| +9% | +$314K | ﹤0.01% | 3088 |
|
|
2018
Q3 | $4.06M | Buy |
186,902
+69,266
| +59% | +$1.15M | ﹤0.01% | 3394 |
|
|
2018
Q2 | $1.79M | Buy |
117,636
+35,427
| +43% | +$668K | ﹤0.01% | 4173 |
|
|
2018
Q1 | $1.62M | Buy |
82,209
+80,547
| +4,846% | +$1.66M | ﹤0.01% | 4187 |
|
|
2017
Q4 | $27K | Buy |
+1,662
| New | +$29.9K | ﹤0.01% | 5997 |
|
Other funds holding DNLI
Morgan Stanley's DNLI Position: Q2 2026 in Review
Morgan Stanley reduced its Denali Therapeutics (DNLI) stake by 13% in Q2 2026, selling an estimated $2.95M and leaving 961,050 shares worth $24.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2908.
Morgan Stanley first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. The position peaked at $50.8M in Q3 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Morgan Stanley held 961,050 shares of Denali Therapeutics worth $24.7M as of Q2 2026.
- Morgan Stanley sold 143,707 Denali Therapeutics shares in Q2 2026, an estimated $2.95M.
- Denali Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2908 holding.
- Morgan Stanley first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Morgan Stanley's Denali Therapeutics position peaked at $50.8M in Q3 2024.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.